Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC With ALK or ROS1 Mutation
NCT05351320Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Apr 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iruplinalkib in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Started Apr 2022; status: recruiting.
02
Drugs
iruplinalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05351320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351320.